Literature DB >> 9546813

Beta-cell rest: a strategy for the prevention of autoimmune diabetes.

F A Karlsson1, E Björk.   

Abstract

An autoantigen being recognized by specific receptors is the key reaction of an autoimmune disease. Whereas much efforts have been made to develop immunosuppressive regimens which reduce the amount of effector cells, and/or inhibit receptor activation, surprisingly little attention has been paid to reduce the ligand-receptor interaction by interfering with the amount of antigen being presented from the target cells. In this review, we discuss clinical observations in autoimmune endocrine disease which illustrate that target cell alterations can modify the disease activity and comment on recent clinical trials which indicate that beta-cell rest may be beneficial to the course of human autoimmune diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9546813     DOI: 10.3109/08916939709003855

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

Review 1.  Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data.

Authors:  Rebecca J Brown; Kristina I Rother
Journal:  Pediatr Diabetes       Date:  2008-01-24       Impact factor: 4.866

2.  Flow distribution during infusion of UW and HTK solution in anaesthetised rats.

Authors:  Leif Jansson; Per-Ola Carlsson; Birgitta Bodin; Orjan Källskog
Journal:  Langenbecks Arch Surg       Date:  2011-02-16       Impact factor: 3.445

3.  Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas.

Authors:  Teresa Vanessa Fiorentino; Francesca Casiraghi; Alberto M Davalli; Giovanna Finzi; Stefano La Rosa; Paul B Higgins; Gregory A Abrahamian; Alessandro Marando; Fausto Sessa; Carla Perego; Rodolfo Guardado-Mendoza; Subhash Kamath; Andrea Ricotti; Paolo Fiorina; Giuseppe Daniele; Ana M Paez; Francesco Andreozzi; Raul A Bastarrachea; Anthony G Comuzzie; Amalia Gastaldelli; Alberto O Chavez; Eliana S Di Cairano; Patrice Frost; Livio Luzi; Edward J Dick; Glenn A Halff; Ralph A DeFronzo; Franco Folli
Journal:  JCI Insight       Date:  2019-10-17

4.  Reduction of beta cell mass: partial insulin secretory compensation from the residual beta cell population in the nicotinamide-streptozotocin Göttingen minipig after oral glucose in vivo and in the perfused pancreas.

Authors:  M O Larsen; B Rolin; C F Gotfredsen; R D Carr; J J Holst
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

5.  Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.

Authors:  Maria Anita Radtke; Ingrid Nermoen; Magnus Kollind; Svein Skeie; Jan Inge Sørheim; Johan Svartberg; Ingrid Hals; Torolf Moen; Gry Høst Dørflinger; Valdemar Grill
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 19.112

6.  Protection of rat pancreatic islets by potassium channel openers against alloxan, sodium nitroprusside and interleukin-1beta mediated suppression--possible involvement of the mitochondrial membrane potential.

Authors:  M Kullin; Z Li; J Bondo Hansen; N Welsh; F A Karlsson; S Sandler
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.